State Street
ORMP icon

State Street’s Oramed Pharmaceuticals ORMP Stock Holding History

State Street’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Buy
+242,100
New +$964K ﹤0.01% 3444
2025
Q3 		– Sell
-66,451
Closed -$150K – 4350
2025
Q2 		$150K Buy
66,451
+1,235
+2% +$2.72K ﹤0.01% 3896
2025
Q1 		$140K Buy
65,216
+4,398
+7% +$10.1K ﹤0.01% 3899
2024
Q4 		$147K Buy
60,818
+762
+1% +$1.81K ﹤0.01% 3913
2024
Q3 		$147K Buy
60,056
+796
+1% +$1.94K ﹤0.01% 3893
2024
Q2 		$152K Buy
59,260
+1,128
+2% +$2.68K ﹤0.01% 3895
2024
Q1 		$170K Buy
58,132
+158
+0.3% +$442 ﹤0.01% 3910
2023
Q4 		$134K Buy
57,974
+1,160
+2% +$2.48K ﹤0.01% 3988
2023
Q3 		$148K Buy
56,814
+1,512
+3% +$4.76K ﹤0.01% 4008
2023
Q2 		$198K Buy
55,302
+1,436
+3% +$4.6K ﹤0.01% 4015
2023
Q1 		$117K Buy
53,866
+2,873
+6% +$9.13K ﹤0.01% 4268
2022
Q4 		$613K Buy
50,993
+4,001
+9% +$31.1K ﹤0.01% 3694
2022
Q3 		$305K Buy
46,992
+983
+2% +$7.96K ﹤0.01% 3965
2022
Q2 		$211K Sell
46,009
-491,661
-91% -$2.63M ﹤0.01% 4173
2022
Q1 		$4.65M Buy
537,670
+25,424
+5% +$260K ﹤0.01% 3219
2021
Q4 		$7.32M Buy
512,246
+24,247
+5% +$507K ﹤0.01% 3064
2021
Q3 		$10.7M Buy
487,999
+136,079
+39% +$2.32M ﹤0.01% 2852
2021
Q2 		$4.71M Buy
+351,920
New +$4.03M ﹤0.01% 3280

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

State Street's ORMP Position: Q2 2026 in Review

State Street opened a new position in Oramed Pharmaceuticals (ORMP) in Q2 2026: 242,100 shares worth $1.16M. The stake represents ﹤0.01% of the portfolio and ranks #3444 among its holdings. This is a return to the name: State Street previously reported a position in ORMP as recently as Q2 2025.

State Street first reported a position in ORMP in Q2 2021 and has held it in 18 quarters since. The position peaked at $10.7M in Q3 2021. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • State Street held 242,100 shares of Oramed Pharmaceuticals worth $1.16M as of Q2 2026.
  • Oramed Pharmaceuticals was a new State Street position in Q2 2026.
  • Oramed Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3444 holding.
  • State Street first reported a position in Oramed Pharmaceuticals in Q2 2021 and has held it in 18 quarters since.
  • State Street's Oramed Pharmaceuticals position peaked at $10.7M in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.